Telix Pharmaceuticals Ltd share price rockets 21% on IPO debut

The Telix Pharmaceuticals Ltd (ASX:TLX) share price rocketed as it made its debut on the ASX this morning.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Telix Pharmaceuticals Ltd (ASX: TLX) share price rocketed 21% to $0.79 as it made its debut on the ASX this morning. Telix is an unprofitable biotech that recently completed an oversubscribed initial public offer (IPO), and its applications were scaled back by 60% due to demand. This will lead to shareholders getting many fewer shares than they'd intended, which may lead to risks if you are aiming to sell in the next few days. Check your allocation before selling.

Telix Pharmaceuticals is conducting research into targeted radiation solutions for treating cancer, and is run by well-regarded CEO Dr Christian Behrenbruch, who also owns 12.5% of the company. Behrenbruch is perhaps most widely known in the investment community for his work on asxlongtail.com, a website aimed at 'demystifying ASX life sciences'. He also has an extensive pedigree in the medical industry.

Is Telix a buy?

Telix is one of the only unprofitable biotech companies I would consider owning shares in, and that's primarily because of the rep of the CEO. This is the guy that was recently quoted in The Australian as saying that a third of Australian biotechs are outstanding, a third are mediocre and wouldn't survive anywhere else, and a third are 'basically fraudulent'.

However, all things considered, I think that Telix is probably unsuitable for the vast majority of investors. It is unprofitable, and its business of medical research is both high risk, costly, and can be very drawn out. CSL Limited (ASX: CSL), it is not. While management thinks they may be able to commercialise a treatment in the next few years, Telix could have quite a way to go to justify today's market capitalisation.

I will be looking at the company more closely in the future, but I think it is a sound suggestion to say that if you do invest, invest only a small amount of your portfolio, be prepared for steep losses and possible capital raisings in the future, and aim to hold for at least 5 years.

Motley Fool contributor Sean O'Neill has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »